Market Report, "Brazil Pharmaceuticals & Healthcare Report Q3 2014", published

The Brazilian pharmaceutical market will continue to be the most attractive to multinational pharmaceutical companies in Latin America. S trong government support, an improving regulatory regime and significant private healthcare growth mean that the market presents significant revenue-generating opportunities for drugmakers and healthcare service providers. However, multinationals will continue to face increasing drug pricing pressure and domestic competition .

Headline Expenditure Projections

* Pharmaceuticals: BRL57.0bn (USD26.4bn) in 2013 to BRL61.8bn (USD25.8bn) in 2014; +8.5% in local currency terms and -2.4% in US dollar terms. Forecast revised upwards from Q214 due to changes to macroeconomic forecast.
* Healthcare: BRL450.0bn (USD208.5bn) in 2013 to BRL496.7bn (USD207.0bn) in 2014; +10.4% in local currency terms and -0.7% in US dollar terms. Forecast revised upwards from Q214 due to changes to historical data.

Full Report Details at
- http://www.fastmr.com/prod/829905_brazil_pharmaceuticals_healthcare_report_q3_2014.aspx?afid=301

Risk/Reward Rating: Brazil scores 62.7 in BMI's Pharmaceutical and Healthcare Risk/Reward Ratings (RRR), making it the third-most attractive pharmaceutical market in America. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected by this quarter's RRR scores.

Key Trends And Developments

* In April 2014 representatives from universities, scientific research institutions and the pharmaceutical industry created the 'Alliance for Clinical Research in Brazil' to promote clinical research and reduce approval times.
* In April 2014, the ANVISA office of pharmaceutical drug market regulation (CMED), fixed the average price increase of medicines to a maximum of 3.35% for 2014 - the lowest price increase approved by CMED in the last five years.
* In March 2014 Bain Capital, a US-based private equity firm, invested BRL2bn (USD880mn) to acquire the Brazilian health insurance operator Grupo Notre Dame Intermedica (GNDI) from its founder Dr....

The Brazil Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazilian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Brazil to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014
- Jordan Pharmaceuticals & Healthcare Report Q3 2014